| Qulipta (atogepant) / AbbVie |
NCT03700320: Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine |
|
|
| Completed | 3 | 744 | US | Standard of Care (SOC) Migraine Preventive Medication, Atogepant | Allergan | Episodic Migraine | 05/20 | 05/20 | | |
ADVANCE, NCT03777059: 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine |
|
|
| Completed | 3 | 910 | US | Atogepant, Placebo | Allergan | Episodic Migraine | 06/20 | 06/20 | | |
|
|
NCT04961671: Effectiveness, Safety, and Tolerability of Analgesics in the Prevention of Chronic Migraine |
|
|
| Completed | 3 | 750 | RoW | atogepant, placebo | Peking University Third Hospital, Allergan Limited 1st Floor Marlow International, The Parkway Marlow, Buckinghamshire SL7 lYL | Chronic Migraine | 11/20 | 05/21 | | |
NCT03939312: Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine |
|
|
| Completed | 3 | 685 | US | Atogepant | Allergan | Episodic Migraine | 03/21 | 03/21 | | |
|
| Completed | 3 | 778 | Europe, Canada, Japan, US, RoW | Atogepant 30 mg, Atogepant 60 mg, Placebo | Allergan | Chronic Migraine | 01/22 | 01/22 | | |
|
NCT04829747: Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine |
|
|
| Completed | 3 | 3 | RoW | Atogepant | Allergan | Chronic Migraine | 01/22 | 01/22 | | |
| Completed | 3 | 315 | Europe, Canada, US, RoW | Atogepant 60 mg, Placebo | Allergan | Episodic Migraine | 08/22 | 08/22 | | |
ECLIPSE, NCT06241313: Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine |
|
|
| Recruiting | 3 | 1300 | Europe, Japan, RoW | Atogepant, Qulipta, Aquipta, Placebo for Atogepant | AbbVie | Migraine | 07/25 | 11/26 | | |
NCT04437433: A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine |
|
|
| Completed | 3 | 186 | Japan | Atogepant 60 mg | AbbVie | Chronic Migraine, Episodic Migraine | 06/24 | 06/24 | | |
NCT04686136 / 2020-002470-27: A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine |
|
|
| Completed | 3 | 596 | Europe, Canada, US, RoW | Atogepant 60 mg | AbbVie | Episodic Migraine, Chronic Migraine | 10/25 | 10/25 | | |
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine |
|
|
| Completed | 3 | 75 | US | Atogepant, QULIPTA | AbbVie | Chronic Migraine | 05/25 | 05/25 | | |
Release, NCT05861427: Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine |
|
|
| Completed | 3 | 523 | Japan | Atogepant, Qulipta, Placebo for Atogepant | AbbVie | Migraine | 03/25 | 03/25 | | |
NCT06806293: Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
|
|
| Recruiting | 3 | 430 | Europe, Japan, RoW | Atogepant, Qulipta, Aquipta, Placebo for Atogepant | AbbVie | Menstrual Migraine (MM) | 02/27 | 07/27 | | |
NCT06810505: A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years |
|
|
| Recruiting | 3 | 420 | Europe, Canada, Japan, US | Atogepant, Qulipta, Aquipta, Placebo for Atogepant | AbbVie | Chronic Migraine | 03/31 | 03/31 | | |
TEMPLE, NCT05748483: Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine |
|
|
| Active, not recruiting | 3 | 545 | Europe, Canada, RoW | Atogepant, QULIPTA, Placebo for Atogepant, Topiramate, Placebo for Topiramate | AbbVie | Migraine | 04/25 | 05/26 | | |
NCT05711394: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689, Placebo-Matching Atogepant | AbbVie | Episodic Migraine | 03/28 | 05/28 | | |
NCT05707949: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine |
|
|
| Enrolling by invitation | 3 | 650 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689 | AbbVie | Migraine Prophylaxis | 04/32 | 04/32 | | |
NCT02848326: Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention |
|
|
| Completed | 2/3 | 834 | US | Atogepant, AGN-241689, Placebo-matching Atogepant | Allergan | Migraine, With or Without Aura | 04/18 | 04/18 | | |
